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Abstract 
Aims Second-generation antipsychotic drugs (SGAs) have a high risk for serious metabolic side-effects 
including dyslipidemia. This study aimed to investigate the acute effects of oral olanzapine treatment on 
the expression of genes for fatty acid and cholesterol biosynthesis in rats. Main methods Female 
Sprague-Dawley rats were treated orally with olanzapine (1 mg/kg, equivalent to a human clinical dose of 
10 mg) via self-administration aimed to measure pharmacokinetics. Based on the pharmacokinetic 
analysis, the acute effects of olanzapine on sterol regulatory element binding protein (SREBP)-related 
fatty acid/cholesterol metabolism genes were investigated in the liver and perirenal white adipose tissue 
(WAT) by Real-time quantitative PCR. Key findings A pharmacokinetic analysis demonstrated that the 
maximum concentration of olanzapine in plasma (Cmax) occurred at 6 h with a peak concentration of 
276.5 ng/ml after a single oral treatment and with a plasma elimination half-life of 3.5 h after peak. The 
mRNA expression of SREBP-2 and target genes for cholesterol synthesis and transport was increased 1.9 
8.8 fold compared with the control at 6 h after olanzapine administration but returned to basal level at 12 
h post-treatment, while the increased mRNA expression of SREBP-1c and its targeted fatty acid-related 
genes appeared at both 6 h and 12 h post-treatment. Significance The present study provided evidence 
that olanzapine at a clinically-relevant dose caused abnormal expression of genes involved in lipid 
metabolism in the liver and WAT. These results suggest that olanzapine may cause dyslipidemia side-
effects through direct effects on lipid biosynthesis and efflux genes associated with SREBP-stimulated 
transcriptional changes. 
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Highlights 
 
•In vivo pharmacokinetics of oral olanzapine treatment in rats 
 
•Olanzapine activates the SREBP-1c-controlling transcription system leading to an increased 
expression of the key genes involved in fatty acid synthesis 
 
•Olanzapine induces a rapid and transient transcriptional upregulation of genes involved in 
cholesterol synthesis via modulation of the expression of SREBP-2 
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Abstract 
Aims:  
Second-generation antipsychotic drugs (SGAs) have a high risk for serious metabolic side-
effects including dyslipidemia. This study aimed to investigate the acute effects of oral 
olanzapine treatment on the expression of genes for fatty acid and cholesterol biosynthesis in 
rats. 
Main methods:  
Female Sprague–Dawley rats were treated orally with olanzapine (1 mg/kg, equivalent to 
human clinical dose of 10 mg) via self-administration aimed to measure pharmacokinetics. 
Based on the pharmacokinetic analysis, the acute effects of olanzapine on SREBP-related 
fatty acid/cholesterol metabolism genes were investigated in the liver and perirenal white 
adipose tissue (WAT) by Real-time quantitative PCR.  
Key findings:  
A pharmacokinetic analysis demonstrated that the maximum concentration of olanzapine in 
plasma (Cmax) occurred at 6 h with peak concentration of 276.5 ng/ml after a single oral 
treatment, with a plasma elimination half-life of 3.5 h after peak. The mRNA expression of 
SREBP-2 and target genes for cholesterol synthesis and transport was increased 1.9 8.8 fold 
compared with the control at 6 h after olanzapine administration but returned to basal level at 
12 h post-treatment, while the increased mRNA expression of SREBP-1c and its targeted 
fatty acid-related genes appeared at both 6 h and 12 h post-treatment.  
Significance:  
The present study provided evidence that olanzapine at a clinically-relevant dose caused 
abnormal expression of genes involved in lipid metabolism in the liver and WAT. These 
results suggest that olanzapine may cause dyslipidemia side-effects through direct effects on 
lipid biosynthesis and efflux genes associated with SREBPs-stimulated transcriptional 
4 
 
changes.  
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Abbreviations 
SREBPs: sterol regulatory element-binding proteins  
SGAs: second-generation antipsychotic drugs  
WAT: white adipose tissue 
Cmax: the maximum concentration of olanzapine in plasma  
AUC: the area under the concentration-time curve 
kel: the elimination rate constant  
t1/2: the elimination half-life 
ALT: alanine aminotransferase 
AST: aspartate aminotransferase 
ALP: alkaline phosphatase 
TG: triglyceride 
TC: total cholesterol 
HDL-C: high density lipoprotein cholesterol 
LDL-C: low density lipoprotein cholesterol 
acc1: acetyl-CoA carboxylase 
fasn: fatty acid synthetase 
scd1: stearoyl-CoA desaturase-1 
ldlr: the low density lipoprotein receptor 
abca1: ATP-binding cassette transporter 1 
soat: sterol o-acyltransferase 
hmgcr: 3-hydroxy-3-methyl-glutaryl- Coenzyme A reductase 
hmgcs: 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 
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1. Introduction 
Second-generation antipsychotic drugs (SGAs), such as olanzapine, have been reported to be 
better tolerated and have improved efficacy in schizophrenia patients; they are widely used as 
first line therapy to control schizophrenia symptoms and other psychotic disorders (Meltzer 
2013). However, olanzapine have the highest risk for serious metabolic side-effects, such as 
obesity, dyslipidemia, and even diabetes (Allison et al 2009; Deng 2013). These metabolic 
side-effects increase risk for cardiovascular disease and premature death (Stahl et al 2009).  
 
While much of the literature has focused on severe weight gain and glucose intolerance, the 
mechanisms underlying SGA-induced dyslipidemia are far from clear. Accumulated evidence 
demonstrated that the sterol regulatory element binding proteins (SREBPs) and target genes 
were thought to be one of possible pathways involved in SGA-induced dyslipidemia (Fernø 
et al 2011; Raeder et al 2006). SREBPs exist as two homologous proteins: SREBP-1 (with 
the splice variants SREBP-1a and SREBP-1c) and SREBP-2. SREBP-1 is known as a key 
regulator of fatty acid synthesis and a molecular link between lipid metabolism, insulin action 
and obesity at the gene regulatory level (Kotzka & Muller-Wieland 2004), while SREBP-2 is 
the main regulator of cholesterol metabolism (Shimano 2001). Clozapine and olanzapine 
induce upregulated expression of SREBPs and target genes in several cell lines, primary rat 
hepatocytes and in vivo 2-week treatment study (Fernø et al 2005; Skrede et al 2012; Yang et 
al 2007). However, in contrast to the findings, acute studies in female rats found that a single 
intraperitoneal (i.p.) injection of clozapine (25 or 50 mg/kg) or olanzapine (5 mg/kg) causes 
an initial upregulation of lipogenic SREBP target genes followed by a marked and sustained 
downregulation of these genes in the liver and WAT (Fernø et al 2009; Jassim et al 2012). 
Although the unexpected biphasic expression pattern of lipogenic SREBP target genes may 
be partly explained by its parallel with the peak serum concentrations of clozapine and short 
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half-life of these SGAs (Jassim et al 2012), considering the high dosages of clozapine and 
olanzapine used in these studies, the biphasic expression pattern is more likely a non-
physiological activation followed by a compensatory rebound effect. Therefore, it is 
necessary to investigate the acute effects of these SGAs at a clinical equivalent dosage on the 
expression of SREBPs and their target genes in relation to lipogenesis/cholesterogenesis in 
the liver and WAT.  
 
It should also be noted that olanzapine may have different pharmacokinetics between i.p. 
injection and oral treatment in rats. Since limited information is available regarding the 
pharmacokinetics of olanzapine in rats, particularly following oral treatment, the 
pharmacokinetics of a single oral olanzapine treatment at a clinically relevant dose (1 mg/kg; 
equivalent to 10 mg in humans at 60 kg body weight) was investigated in this study. Based on 
the pharmacokinetic analysis, the immediate effects of olanzapine (a single oral dose at 
1mg/kg) on SREBP-related fatty acid/cholesterol metabolism genes were investigated in the 
liver and WAT of female rats.  
 
2. Materials and Methods 
  2.1. Animals and Housing 
Female Sprague-Dawley (SD) rats (200-220 g) were obtained from the Animal Resource 
Centre (South-West Hospital, Chongqing, China). After one week of environmental 
familiarization, they were housed in individual cages and allowed ad libitum access to water 
and a standard laboratory chow diet (3.9 kcal/g; 10% fat, 74% carbohydrate and 16% protein) 
under environmentally controlled conditions (22°C, with light cycle from 07:00-19:00 and 
dark cycle from 19:00-07:00) throughout the experimental period. Prior to drug treatment, 
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rats were trained to self-administer a sweet cookie dough pellet (0.3 g, including 30.9% 
cornstarch, 30.9% sucrose, 6.3% gelatine, 15.5% casein, 6.4% fibre, 8.4% minerals and 1.6% 
vitamins) without drugs twice daily (b.i.d.) for one week (Deng et al 2012; Lian et al 2013) 
and were randomly assigned to one of following experiments (n=6/group). All animal 
experiments were conducted in accordance with the National Institute of Health Guide for the 
Care and Use of Laboratory Animals (Publication No. 85-23, revised 1985), with the 
approval of the Scientific Investigation Board of Southwest University, Chongqing.  
 
  2.2. Pharmacokinetic study in rats treated with a single oral dose of olanzapine 
   2.2.1. Sample preparation and analysis 
Six rats were fasted overnight and treated with a single oral dose of olanzapine (1 mg/kg 
body weight; Eli Lilly, USA) via a cookie dough pill at ~09:00 am. Immediately following 
dosing, orbital blood samples were collected at 0, 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 h in 
heparinized tubes, then centrifuged (1000 g,10 min, 4 °C) to separate the plasma which was 
stored at -80°C until assay. A 0.1 ml sample of plasma was extracted using 0.5 ml butyl 
acetate: dichloromethane (4:1) adding 2 μl 10% (m/v) vitamin C. The sample mixture was 
mixed on a vortex mixer for 1 min, and centrifuged for 10 min (16000 g). The upper organic 
layer was separated, dried under N2 flow, and then dissolved again in a total volume of 50 μl 
of HPLC grade methanol. The olanzapine assay was developed on an Agilent Eclipse XDB-
C18 column (4.6 mm × 250 mm, 5 µm). Mobile phase A was 0.3% triethylamine in water 
with the pH adjusted to 3.73 by acetic acid, with methanol as mobile phase B (Morin et al 
2005). The flow rate of the mobile phase was maintained at 1ml/min, while elution was 
conducted in gradient mode as shown in Table S1 (available online). The detection was 
carried out by UV detector at 254 nm (Cui et al 2011).  
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Standard stock solutions were prepared by dissolving olanzapine in methanol to yield a 
nominal concentration of 1 mg/ml. The solutions were subsequently further diluted in 
methanol to produce working standards. Calibration samples of olanzapine (0.1, 0.2, 0.4, 1, 2, 
4, 10 and 20 μg/ml) were prepared by spiking blank plasma with appropriate quantities of 
working standard solutions. Calibration curves in the 0.1-20 µg/ml range were constructed by 
plotting the ratios of peak area against concentration. The concentrations of olanzapine in the 
test samples were calculated using regression parameters obtained from the standard curve.  
 
   2.2.2. Pharmacokinetic analysis 
All pharmacokinetic parameters of olanzapine were calculated from the plasma concentration 
versus time using the Data Analysis Pharmacokinetic software DAS 2.0 (Mathematical 
Pharmacology Professional Committee of China, Shanghai, China). A non-compartmental 
model was used to determine the pharmacokinetic parameters of olanzapine. Maximum 
concentration (Cmax) of the drug in plasma after a single oral dose (1 mg/kg) was calculated 
from the recorded data. The area under the concentration-time curve (AUC) was calculated 
by using the log-linear trapezoidal rule. The elimination rate constant (kel) was derived from a 
linear regression of the terminal log-linear disposition phase of the concentration-time curve. 
The elimination half-life (t1/2) was calculated as ln2/kel (Aravagiri et al 1999).  
 
  2.3. Acute effects of olanzapine on SREBP-controlled genes in relation to lipogenesis and 
cholesterogenesis  
    2.3.1. Animal treatment 
Twenty-four rats were fasted overnight, and administered a single oral treatment of 
olanzapine (1 mg/kg) or vehicle (n=12) at ~09:00 am as described above. Based on the 
findings in the pharmacokinetic study, treated and control rats were sacrificed by carbon 
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dioxide asphyxiation at 6 h (n=6/group) or 12 h (n=6/group) after drug treatment. The liver 
and perirenal WAT were collected and frozen in liquid nitrogen immediately followed by 
storage in a -80 °C freezer until further analysis. Cardiac blood was collected in procoagulant 
tubes, left at 37°C for 30 min and centrifuged at 1000 g for 10 min. Serum was transferred to 
pre-cooled Eppendorf tubes immediately after centrifugation and stored at -20 °C. 
 
   2.3.2. Measurements of liver enzymes and serum lipids  
Liver enzymes, biochemical parameters (the serum levels of TG, total cholesterol, LDL-C 
and HDL-C) were measured by colorimetric method using an Olympus AU400 chemistry 
analyser (Olympus, Tokyo, Japan).  
 
   2.3.3. RNA extraction, cDNA synthesis, and gene expression analysis 
Total RNA of liver or perirenal WAT was extracted using an RNAsimple Total RNA Kit 
(DP419) (TianGen, China). To avoid amplification of contaminating genomic DNA, RNA 
samples were digested with DNase I (Takara, Dalian, China). First strand cDNA was 
synthesized using the cDNA synthesis kit (DingGuo, China). Cycles were set as follows: 60 
min at 42°C, and 5 min at 95 °C, 5 min at 4 °C. Quantitative PCR was performed in a Bio-rad 
CFX Connect™ Real-Time PCR Detection System using 96-well microliter plates with a 
final volume of 20 μl mix [composed of 2×10-3 nM of specific primers (Invitrogen, China), 8 
μl of water, 10 μl of the SYBR® GreenER™ qPCR SuperMix from Invitrogen™, and 2 μl of 
diluted cDNA]. Thermal cycling parameters were 2 min at 95 °C, followed by 40 cycles each 
containing 30 s at 94 °C, 30 s at 60 °C , and 30 s at 72 °C. Based on the previous report 
(Skrede et al 2012), primers (see Table S2) (available online) were designed from sequences 
in the Genbank databases using Primer 5 software. Each primer pair was then validated by an 
efficacy ≥95%. All samples were analysed in duplicate. In a pre-experiment, all genes 
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expression levels were normalized relative to two endogenous controls, β -actin 
(Actb) and glyceraldehyde-3-phosphate dehydrogenase (Gapdh), which showed stable 
and similar results with both housekeeping genes. Since Gapdh was more strongly 
expressed and showed the higher level of accuracy in Ct value than Actb in the pre-
experiment, Gapdh was chosen as the endogenous control gene in this study. Results 
were expressed in relative expression using the comparative 2-ÄÄCt method. The mean value 
of the control group was set at 1 and all data were normalized versus control group.  
 
2.4. Statistical analysis 
Data were expressed as mean ± SEM, and all data were analysed using the SPSS program 
(IBM version 19.0, SPSS Inc., USA). Due to the small sample size (6 rats/group), data were 
analysed using the Kruskal–Wallis H test, followed by a post-hoc Mann-Whitney U test at 
each time point. Statistical significance was accepted when p<0.05. 
 
3. Results 
  3.1. Pharmacokinetic parameters of a single oral dose olanzapine  
The calibration curve was linear within the concentration range assayed. The mean regression 
value of the calibration curve was y = 27.06x -1.2095 (r2 = 0.9973) for olanzapine. After 
olanzapine was orally self-administered via cookie dough to the rats, the plasma 
concentration versus time profile was shown in Fig.1. The Cmax occurred at 6 h after oral 
administration and the elimination half-life (t1/2) was 3.5 h after the peak. The major 
pharmacokinetic parameters of olanzapine are listed in Table 1.  
 
  3.2. Serum biochemical parameters  
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Table 2 presents the levels of TG, total cholesterol, HDL-C, LDL-C, alanine aminotransferase, 
aspartate aminotransferase, and alkaline phosphatase at 6 h or 12 h after a single oral dose of 
olanzapine. Compared with the control group, there was only a tendency for increase in liver 
aspartate aminotransferase levels (115±16%, p=0.091), while in the plasma lipid there were 
no significant changes at any time point after a single oral olanzapine treatment. 
 
  3.3 mRNA expression levels of fatty acid synthesis-related genes in the liver and WAT 
As shown in Fig. 2A, there was upregulation of SREBP-1c mRNA expression in the liver at 
both examined time points compared to controls (2.1-fold at 6 h, and 3.5-fold at 12 h, p<0.05). 
Consistent with the alteration of srebp-1c, fatty acid synthetase (fasn) mRNA expression was 
significantly higher at the time points in the treatment group after the single oral olanzapine 
dose (4.7-fold at 6 h and 3.4-fold at 12 h respectively, all p<0.05). However, there was no 
significant difference observed between the olanzapine and control groups in the acetyl-CoA 
carboxylase (acc1) expression level after drug treatment. 
 
Similar to the liver, srebp-1c, acc1 and fasn involved in fatty acid biosynthesis were over-
expressed in viceral WAT after one oral dose treatment of olanzapine (Figs. 2A and 2B). 
However, unlike the liver, there was a stronger upregulation of the mRNA expression for 
these genes at 12 h than at 6 h post-treatment. In particular, the srebp-1c expression level was 
significantly increased (up to 9.7-fold) at 12 h (p<0.01). The maximal upregulated response 
was recorded for the expression of fasn gene at 12 h post-treatment (11.13-fold, p<0.01; Fig. 
2B).   
 
3.4 mRNA expression levels of cholesterol biosynthesis and transport-related genes in the 
liver and WAT  
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As presented in Fig. 3A, olanzapine affected mRNA expression of SREBP-2 and its target 
genes, with a significant difference between expression at 6 h and 12 h after oral treatment. 
The mRNA levels of these genes were significantly increased at 6 h, followed by a sharp 
decrease, and a return to baseline (the control level) at 12 h. In the observed period, srebp-2 
(3.57-fold increase, p<0.05) and its target genes hmgcs (4.64-fold increase, p<0.01) and 
hmgcr (8.82-fold increase, p<0.05) were significantly stimulated only at 6 h after drug 
administration when the plasma concentration of olanzapine peaked at 276.5 ng/ml. For ATP-
binding cassette transporter 1 (ABCA1), a cholesterol efflux pump in the cellular lipid 
removal pathway (Schmitz & Langmann 2001), its mRNA was found to be overexpressed in 
the liver, leading to a 3.48-fold increase (p<0.05). For sterol o-acyltransferase (SOAT), a key 
enzyme in controlling cholesterol absorption, the up-regulated expression of mRNA appeared 
only at 6 h after drug administration (p<0.05; Fig.3A).    
  
In visceral WAT from olanzapine-treated rats, similar to the pattern in the liver, a drug-
induced increase of cholesterol biosynthesis-related genes was observed only at 6 h post-
treatment (Figs. 3A and 3B). The maximal upregulated response was recorded for the 
expression of srebp-2 at 6 h post-treatment (10.42-fold; p<0.01). However, 12 h after oral 
treatment of olanzapine, all genes examined returned to the baseline.  
 
4. Discussion 
In this study, we examined the direct effect of olanzapine (1mg/kg) in inducing 
transcriptional activation of SREBPs and SREBP-controlled lipid-related genes in female rats 
after a single oral treatment. Pharmacokinetic analysis showed that the Cmax and elimination 
half-life of olanzapine were 276.5 ng/ml and 3.5 h, respectively. Further analysis of the gene 
expression showed that olanzapine activated the SREBP-1c-controlling transcription system, 
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and then led to a continuous stimulation of the key genes involved in fatty acid synthesis until 
at least 12 h after treatment, while, a rapid and transient transcriptional upregulation of the 
genes involved in cholesterol metabolism was observed at 6 h post-treatment and returned to 
normal via modulation of the expression of SREBP-2 after 12 hours of treatment. Our data 
provide further evidence that transcriptional deregulation via upregulation of mRNA of 
SREBPs transcription factors may contribute to olanzapine-induced disturbance in lipid 
metabolisms.  
 
Although olanzapine oral administration is frequently used in clinics, a majority of previous 
studies in animals were through intraperitoneal (i.p.) injection (Fell et al 2008; Fernø et al 
2009; Jassim et al 2012) or continuous delivery via a minipump (Mann et al 2013; van der 
Zwaal et al 2008). Neither i.p. injection nor minipump delivery closely mimic clinical oral 
treatment conditions, because they may have different pharmacokinetics from oral 
administration in rats. The oral dose of 1 mg/kg olanzapine is equal to about 10 mg in human 
(60 kg body weight) according to dosage translation between species based on body surface 
area following the FDA guideline (FDA 2005; Reagan-Shaw et al 2008), and this is among 
the recommended clinical dosages for treating schizophrenia patients (Kantrowitz & Citrome 
2008). Although our previous studies have successfully established a female rat model for 
olanzapine-induced metabolic side-effects using oral treatment of 1mg/kg olanzapine (Lian et 
al 2014; Weston-Green et al 2011; Weston-Green et al 2012), to better understand the 
mechanism of dyslipidmia, it is important in further studies to employ multiple doses for 
investigating the dose-response effects on gene transcription. 
 
In this study, the maximum plasma concentration was 276.5 ng/ml at 6 hours after one oral 
administration of 1mg/kg olanzapine in cookie dough. The observation was not consistent 
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with previous findings in the peak time. In an earlier study, a rapid absorption was observed 
and the peak appeared within 45 min after an oral gavage of 6 mg/kg olanzapine (Aravagiri et 
al 1999). In another study, after a single intraperitoneal dose of 5 mg/kg, the serum level of 
olanzapine peaked at 1 h after injection (Jassim et al 2012). Since olanzapine was prepared 
with the cookie dough in this study, a most likely explanation for the delay of drug absorption 
was due to a prolonged release of olanzapine from the cookie mix and/or delayed 
gastrointestinal absorption (Mauri et al., 2007). Another explanation is that olanzapine could 
be absorbed faster at the higher dose (5-6 mg/kg) used in previous reports (Aravagiri et al 
1999; Jassim et al 2012). In the current study, the volume of distribution and clearance 
characteristics of olanzapine resulted in an elimination half-life of 3.5 h, which was slightly 
longer than the 2.5 h reported in male rats by Aravagiri (Aravagiri et al 1999). This is 
probably because of the differences in metabolic capacity of the cytochrome P450 (CYP450) 
isoenzyme system between male and female rats. It is well recognized that CYP450 mediated 
oxidation is the primary metabolic pathway for olanzapine (Azzaro et al 2007; Sheehan et al 
2010). Interestingly, clearance of olanzapine has been reported to be approximately 30% 
higher in men than women, due to the differences in metabolic capacity of CYP450 beteween 
males and females (Gervasini et al 2013; Kelly et al 1999). Therefore, elimination half-life of 
olanzapine in females might be slightly longer than those in males. Finally, based on a 3.5 h 
elimination half-life of olanzapine, 6-h and 12-h time points after a single oral-administration 
were chosen to detect the effects of olanzapine on mRNA expression of hepatic and WAT 
genes.  
 
Olanzapine was observed to induce a direct transcriptional upregulation of SREBPs and its 
target genes in the liver in the present study. At 6 h post-treatment, olanzapine caused a 
significant increase in the expression of both srebp-1c and its downstream target genes (e.g. 
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acc1 and fasn), as well as srebp-2 and its downstream cholesterogenic genes (e.g. hmgcs, 
hmgcr and ldlr). Our current data confirmed the previous in vitro findings of a direct 
antipsychotic drug effect on expression of genes including de novo lipogenesis and 
cholesterogenesis. Studies in rat primary hepatocytes (Lauressergues et al 2010; Oh et al 
2011), or liver cell lines of THLE-3and HepG2 (Raeder et al 2006; Yang et al 2007) have 
shown upregulation of the transcription factors srebp-1 and/ or srebp-2 after clozapine or 
olanzapine treatment. Since olanzapine did not promote significant changes in blood TC, TG, 
HDL-C, LDL-C after 6 or 12 hours of a single treatment in this study, these mRNA changes 
observed should not be a feedback effect of dyslipidemia. Therefore, these data suggest that 
olanzapine-mediated transcriptional upregulation of SREBPs and their target genes might be 
a direct treatment effect. Once activated by olanzapine, SREBPs may start to induce de novo 
lipogenesis and cholesterogenesis. This could lead to a sequence of steps stimulating an 
abnormal production of fatty acid and cholesterol under chronic treatment of olanzapine.  
 
In the present study, responding to olanzapine treatment, transcriptional activation patterns 
were different between lipogenic genes and cholesterogenic genes. As shown in Figs. 2 and 
3, there was a clear trend in the transient changes in the expression of SREBP-2-controlled 
cholesterol metabolism genes following olanzapine treatment: the initial upregulation was 
followed by a marked return to the basal level at 12 h after olanzapine treatment, 
corresponding with a peak serum concentration of olanzapine at 6 h followed by a rapidly 
declining serum drug concentration. In contrast, srebp-1 and target lipogenic genes such as 
fasn and acc1 showed a different expression pattern: an early upregulation was followed by a 
sustained activation of transcription at 12 h after olanzapine treatment in both the liver and 
visceral WAT (Figs. 2A and 2B), which suggested that the expression of srebp-1 and its 
target lipogenic genes was not affected by the decline in serum olanzapine concentration at 
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12 h post-treatment. However, it is very interesting that a different (biphasic) expression 
pattern of lipogenic genes and cholesterol metabolism genes was reported previously in 
female rats: an i.p. injection of olanzapine (5mg/kg) or clozapine (25mg/kg or 50mg/kg) 
induced an initial upregulation of SREBP-controlled gene expression followed (at around 1 h 
post-treatment) by a marked downregulation of SREBPs target genes in rats (Fernø et al 
2009; Jassim et al 2012). Although the initial upregulated expression of SREBPs target genes 
may be explained by the parallel peak concentration of serum drug concentration observed in 
these studies, the following downregulation could not be well explained by the serum drug 
concentration. Given the high dosages of clozapine and olanzapine used in these studies, the 
biphasic expression pattern is more likely a non-physiological activation followed by a 
compensatory rebound effect (Fernø et al 2009; Jassim et al 2012). Therefore, the gene 
expression patterns observed in the current study are most likely physiological responses to 
olanzapine treatment at a clinical equivalent dosage. Since srebp-1c and its downstream 
target fatty acids biosynthesis genes (e.g. acc1 and fasn) showed a consistent expression 
pattern compared to srebp-2 and its downstream cholesterogenic genes (e.g. hmgcs, hmgcr 
and ldlr), our findings should be one possible explanation for the clinical feature that 
dyslipidemia in the form of hypertriglyceridemia occurs more frequently than 
hypercholesterolemia in patients treated with SGAs (Birkenaes et al 2008; Sadibasic et al 
2014).  
 
Our study revealed that the expression of srebp-1, srebp-2 and their target genes in WAT 
displayed a similar pattern as in the liver after one single oral treatment of olanzapine. 
Consistently with this, a previous study reported an upregulation of srebp-1 and SREBP-1-
related adipogenesis in the 3T3-L1 adipocyte cell line (Yang et al 2007). However, an in vivo 
study has reported that, following one i.p. injection of olanzapine (5mg/kg), a non-significant 
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initial upregulation of lipid-related genes was observed in mesenteric WAT, although a 
significant upregulation was caused in the liver with the same treatment (Jassim et al 2012). 
Of note, in this study, a greater expression of srebp-1c and fatty acid biosynthesis-related 
genes (acc1 and fasn) was observed in WAT than in the liver, particularly at 12 h (Fig. 2). It 
was not clear what factor(s) caused the greater effect on gene expression in WAT. However, 
several lines of evidence have proved that the WAT played a more important role in de novo 
lipogenesis than the liver (Pearce 1983; Swierczynski et al 2000). Parasympathetic inputs to 
adipose tissue modulates glucose uptake and free fatty acid metabolis (Kreier et al 2002) and 
has selective effects on local hormone synthesis controlling the specific activities of lipogenic 
enzymes (Fliers et al 2003). Cholinergic muscarinic receptors are present in WAT (Yang et al 
2009). Therefore, it is possible that the greater expression of fatty acid-related genes in the 
WAT was induced by olanzapine through activation of parasympathetic nerves. Although our 
present knowledge on the regulation of srebp-1 expression in the WTA is far from complete, 
it has been shown that tissue-specific expression of SREBP-1 is responsible for the 
differential expressions of lipogenic genes between the liver and adipose tissue (Foretz et al 
1999). In addition, the SREBP-1 may play additional roles in adipose tissue. For example, 
overexpression of SREBP-1 in cultured 3T3-L1 preadipocytes was shown to promote 
adipocyte differentiation induced by activation of peroxisome proliferator-activated receptor-
gamma (PPARγ), a known activator of adipocyte differentiation (Kim & Spiegelman 1996; 
Sertie et al 2011). Indeed, antipsychotic treatments alter the gene expression patterns in 
adipocytes in coordinated fashion (Sarvari et al 2014). Hence, it is important to further 
investigate the roles of SREBP in adipogenesis. 
 
One limitation of this study was that only olanzapine was examined in this study. 
Interestingly, it was recently demonstrated that clozapine and risperidone elicited significant 
19 
 
inductions of SREBP-1 maturation and FASN mRNA expression in primary cultures of rat 
hepatocytes and 3T3-L1 cells associated with an increase of triacylglycerol (Hu et al 2010; 
Lauressergues et al 2011). Therefore, it is also important in further study to compare the 
effects of these antipsychotics on inducing SREBP-controlled transcriptional activation of 
lipogenesis in the liver and WAT.  
 
In summary, olanzapine can directly affect the expression of lipid metabolism genes through 
regulation of SREBP in the liver and WAT. In addition, SGAs have high binding affinities 
with multiple neurotransmitter receptors, such as the 5-HT2C (5-HT2CR), histamine H1 (H1R) 
and muscarinic M3 receptor (M3R) (Correll 2010), which are associated with SGA-induced 
metabolic side-effects such as weight gain and diabetes (Correl et al 2012; Deng 2013; 
Nasrallah 2008). Further research is important to identify the role of these peripheric 
neurotransmitter receptors in SGA-induced dyslipidemia. If these relationships can be fine-
tuned, the genes involved in lipid metabolism might be promising targets for pharmacological 
intervention to control the metabolic-side effects caused by SGAs. 
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Figure 1 
Plasma concentration-time profile (n=6) of olanzapine (mean ± SEM) after administering an 
oral dose of 1 mg/kg to female SD rats weighing 200-220 g. The parent drug was isolated 
from plasma by liquid-liquid extraction with butyl acetate: dichloromethane (4:1) and 
analyzed by HPLC. 
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Figure 2 
The effects of olanzapine on gene expression involved in fatty acid biosynthesis. Relative 
expression levels of (A) fatty acid biosynthesis genes in the liver, (B) fatty acid biosynthesis 
genes in the perirenal white adipose tissue (WAT). Total RNA was extracted and gene 
expressions were quantified using Q-PCR at 6 h and 12 h after a single oral treatment with 1 
mg/kg olanzapine. mRNA expression levels were normalized to the expression of 
housekeeping gene gapdh. Each column is the mean ± SEM (n=6). *, p<0.05; **, p<0.01. 
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Figure 3    
The effects of olanzapine on gene expression involved in cholesterol biosynthesis and 
transport. Relative expression levels of (A) cholesterol biosynthesis and transport genes in the 
liver, (B) cholesterol biosynthesis and transport genes in WAT. Total RNA was extracted and 
gene expressions were quantified using Q-PCR at 6 h and 12 h after a single oral treatment 
with 1 mg/kg olanzapine. mRNA expression levels were normalized to the expression of 
housekeeping gene gapdh. Each column is the mean ± SEM (n=6). *, p<0.05; **, p<0.01
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Table 1  Pharmacokinetic parameters of olanzapine after a single oral dose treatment in 
female SD rats 
Parameters Olanzapine 
 Mean %CV 
Cmax(ng/ml) 276.5 29.75 
tmax(h) 6.0 0 
AUC0→24 (ng* h/ml) 38578 35.60 
AUC0→∞(ng* h/ml) 78636 53.36 
t1/2 (h)  3.5 32.28 
MRT (h) 10.213 14.92 
Cl/F (ml/h/kg)   206.78 32.82 
Vd/F (ml/kg) 2860.13 28.64 
Cmax, peak plasma concentration; tmax, time to reach peak plasma concentration; AUC0→∞, 
area under the concentration–time curve from zero to infinity; AUC0→24, area under the 
concentration–time curve from zero to the last measurable plasma concentration; t1/2, 
elimination half-life; MRT, mean residence time; Cl/F, clearance; Vd/F, volume of 
distribution. 
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Table 2  Serum lipid levels and other biochemical parameters following olanzapine oral administration to rats 
 
Time 
point 
group ALT 
(U/L) 
AST 
(U/L) 
AST/ALT ALP 
(U/L) 
TG 
( mmol) 
TC 
( mmol/L) 
HDL-C 
( mmol/L) 
LDL-C 
( mmol/L) 
6 h  
post-dose 
Control 1 24.40±1.96 65.40±6.73 2.68±0.15 110.40±3.03 0.50±0.07 1.35±0.06 1.14±0.05 0.45±0.04 
Treatment 1 25.50±1.67 76.50±2.95 3.04±0.15 120.67±11.74 0.51±0.06 1.32±0.13 1.13±0.11 0.44±0.05 
12 h  
post-dose  
Control 2 29.20±1.91 76.60±4.62 2.64±0.14 99.00±16.47 0.68±0.07 1.51±0.07 1.32±0.06 0.48±0.02 
Treatment 2 31.67±2.81 88.17±12.39 2.75±0.17 117.50±12.06 0.67±0.08 1.40±0.16 1.24±0.14 0.44±0.06 
 
The levels (mean ± SEM) of serum ALT, AST, ALP, TG, TC, HDL-C, and LDL-C were measured in rats exposed to a single oral dose of 
olanzapine (1 mg/kg). The changes in the amount of lipids were measured at 6 h and 12 h after olanzapine administration (n=6/group). ALT, 
alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; TG, triglyceride; TC, total cholesterol; HDL-C, high 
density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.  
